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Despite	 remarkable	 advances	 in	 our	 understanding	 of	 this	
condition,	 and	 the	 availability	 and	 current	 development	 of	 novel	
medications	 for	 the	 treatment	 of	 asthma,	 many	 asthma	 patients	












sure	 appropriate	 support	 to	meet	 these	needs.	 Provisions	 to	 ensure	
better	asthma	control	at	an	earlier	stage	may	facilitate	improved	quality	







2  | UNMET NEEDS IN PEDIATRIC A STHMA
2.1 | Guidelines that acknowledge the management 
of different asthma phenotypes
Diagnosing	asthma	and	establishing	control	as	early	as	possible	 in	
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Asthma	is	not	a	simple,	single	disease	entity;	the	existence	of	a	
variety	of	clinical	presentations	(phenotypes)	and	underlying	mech‐












developmental	 milestones	 (and	 indeed	 underlying	 each	 distinct	
phenotype).19	 Such	 knowledge	 may	 facilitate	 the	 development	 of	
mechanism‐	or	phenotype‐driven	 treatment	options	 in	 children	 to	
establish	control	in	the	early	stages	of	asthma.
The	Global	Initiative	for	Asthma	(GINA)	definition	of	asthma	was	
recently	updated;	asthma	is	proposed	to	be	“a heterogeneous disease, 
usually characterized by chronic airway inflammation. It is defined by 
the history of respiratory symptoms such as wheeze, shortness of breath, 
chest tightness and cough that vary over time and in intensity, together 




conditions	 too	 and	 can	 be	misdiagnosed	 as	 asthma	 in	 young	 chil‐
dren,	 leading	 to	 the	 inappropriate	 prescription	 of	 inhaled	 cortico‐
steroids	 (ICS).	 Furthermore,	 the	 relationship	 between	 pre‐school	
wheeze	and	asthma	remains	debatable.20	In	children,	an	increase	in	
post‐bronchodilator	 reversibility	as	measured	by	 forced	expiratory	
volume	 in	 one	 second	 (FEV1)	 of	 >12%	 predicted	 is	 recommended	
to	 fulfill	 the	 variable	 expiratory	 airflow	 limitation	 criterion	 of	 the	





pulse	oscillometry	 can	be	 challenging	 in	 young	children,	making	 it	
difficult	to	conclusively	meet	the	definition	of	asthma.22,23	In	these	
cases,	 asthma	diagnosis	 is	 essentially	based	on	 clinical	 criteria.	Of	




is	 not	 a	 new	 phenomenon	 and	 is	 evidenced	 by	 the	 differing	 ap‐
proaches	 currently	 in	 existence.	 These	 discrepancies	 have	 been	









Furthermore,	 it	 is	 not	 clear	 to	what	 extent	 the	 severity	 gradi‐
ent	observed	among	asthma	patients	and	mentioned	in	guidelines,	
that	is,	mild,	moderate,	and	severe	asthma,	represents	a	continuous	




















ant	 position	 to	 identify	 uncontrolled	 or	 difficult‐to‐treat	 asthma.	
The	 importance	of	 local	 factors	 in	the	primary	care	setting	should	
not	 be	 overlooked;	 local	 environmental	 triggers	 of	 symptoms	 and	
















Increased	 awareness	 of	 effective	 referral	 strategies	 and	 im‐
proved	communication	between	GPs/PCPs	and	specialists	may	im‐
prove	 the	 rate	 of	 appropriate	 referrals.29	 The	 time	 to	 referral	will	
ultimately	depend	on	local	healthcare	regulations	and	resources	of	
GPs/PCPs.14	 Local	 implementation	 of	 strategies	 to	 support	 GPs/
PCPs	 in	 the	 delivery	 of	 pediatric	 asthma	 care	 and	 appropriate	
PAPADOPOULOS et AL.10  |    
referral	guidelines	may	improve	clinical	outcomes	for	children	with	
asthma.	Referral	of	pediatric	patients	with	severe	asthma	to	a	spe‐
cialist	 should	 be	 considered	 with	 high‐priority	 status,	 even	 if	 the	










pharmacological	 intervention,	 including	 controller	medication,	 res‐
cue	medication,	and	add‐on	therapy,	in	the	case	of	severe	asthma.12 
Equally	 as	 important	 are	 the	 non‐pharmacological	 treatment	 ap‐
proaches,	which	are	 frequently	underestimated.	These	 include	pa‐
tient	 education	 and	 trigger	 avoidance	 (eg,	 minimizing	 exposure	 to	
pollutants	and	allergens	to	reduce	asthma‐associated	morbidity).34,35
Corticosteroids	 play	 a	 central	 role	 in	 the	 pharmacological	
management	 of	 asthma.	Over	 the	 last	 six	 decades,	 the	 clinical	 ef‐
fectiveness	of	corticosteroid	treatment	in	asthma	has	been	demon‐
























F I G U R E  1  Present	inadequacies	and	
potential	future	realities	of	pediatric	
asthma	management
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Furthermore,	 delivery	 via	 the	 inhaled	 route	 can	 be	 ineffective	
in	children	<5	years	 in	whom	drug	deposition	 to	 the	 lungs	may	be	




there	 are	 non‐frequent,	 but	 potentially	 serious,	 adverse	 effects	
associated	 with	 their	 use.	 These	 include	 possible	 height	 deficits,	
increased	 susceptibility	 to	 infection,	 and	 hypothalamic‐pituitary‐
adrenal	(HPA)	axis	suppression,	potentially	leading	to	adrenal	crisis	
or	growth	retardation	 in	children.44‐47	As	the	 incidence	of	adverse	
events	 is	 often	 dose‐dependent,	 the	 minimum	 effective	 dose	 in	
order	to	achieve	uncompromised	asthma	control	should	always	be	
considered.44
As	 per	 clinical	 guideline	 recommendations,	 short	 courses	 of	
oral	 corticosteroids	 (OCS)	 are	 used	 to	 effectively	 treat	 exacer‐
bations.12	 However,	 frequent	 OCS	 use	 for	 exacerbations,	 espe‐
cially	at	higher	doses,	 is	associated	with	a	wide	range	of	adverse	
effects	 in	children	 including	growth	 impairment,48 reduced bone 
density,46	and	behavioral	effects.49	Also,	the	association	between	
OCS	 and	 bone	 fractures	 has	 been	 highlighted	 in	 a	 recent	multi‐
variate	analysis	which	demonstrated	a	17%	increased	risk	of	bone	
fracture	in	pediatric	patients	after	one	OCS	prescription	compared	








in	 combination	 with	 an	 ICS.	 Of	 note,	 the	 black	 box	 warning	 on	
medicines	 containing	 both	 an	 ICS	 and	 a	 LABA	was	 recently	 re‐
moved	by	the	US	Food	and	Drug	Administration,	presumably	af‐
fording	more	“peace	of	mind”	to	HCPs	and	caregivers	of	children	
receiving	 these	medications.	 Tiotropium	 is	 a	 long‐acting	musca‐
rinic	 antagonist	 (LAMA)	 recently	 approved	 for	 children	with	 se‐
vere	asthma	≥6	years	of	age,	providing	another	treatment	option	
for	GINA	step	4	and	5	patients.	Furthermore,	in	patients	≥6	years	
of	 age	with	 severe	 asthma,	 add‐on	 anti‐IgE	 therapy	with	 omali‐
zumab	 has	 shown	 clinical	 efficacy	 and	 also	 reduces	 OCS	 use.51 
Similar	efficacy	data	are	still	unavailable	for	patients	<6	years	due	
to	a	lack	of	appropriate	studies.
3  | POTENTIAL FOR BIOLOGIC S A S 
NON‐STEROID ‐BA SED TRE ATMENTS IN 
PEDIATRIC A STHMA
An	important	question	in	the	era	of	stratified	medicine	is	what	can	
be	 done	 beyond	 corticosteroids.	 Stratified	 or	 personalized	 medi‐
cine	recognizes	that	the	underlying	mechanisms	of	asthma	can	vary	









disease	 progression;	 however,	 asthma	management	 in	 very	 young	
patients	 is	 based	 largely	 on	 clinical	 judgment,	 expert	 opinion,	 and	
cost	of	medications	owing	to	the	lack	of	clinical	evidence	in	this	par‐
ticular	patient	population.54	As	described	previously	by	Szefler	and	










symptoms	 that	 are	 not	 sufficiently	 controlled	with	 ICS	monother‐
apy.56	 This	 labeling	 excludes	 asthma	 patients	 <6	years	who	might	
benefit	from	anti‐IgE	therapy	and	limits	the	add‐on	therapy	options	





some	countries)	with	eosinophilic	asthma,	and	 it	 is	encouraging	 to	
note	that	other	anti‐IL‐5Rα	and	anti‐IL‐4Rα	 therapies	are	currently	
under	investigation	in	patients	≥12	years.53	Although	the	results	of	
studies	of	 these	biologics,	 including	mepolizumab57,58 and benrali‐
zumab,59,60	are	a	very	positive	step	forward	for	patients	with	asthma,	
















has	 suggested	a	 favorable	 long‐term	safety	profile	 in	 children	and	
adolescents,62	all	other	biologic	therapies	need	to	demonstrate	the	




An	unmet	need	 that	 is	particularly	 relevant	 for	young	children	




age.63	 Although	we	 have	 observed	 some	 promising	 data	with	 im‐
munotherapy	 in	 children	 (5–12	years)	 to	 date,64	 studies	 assessing	
current	asthma	therapies	in	infants	have	been	sparse.	It	is	possible	
that	omalizumab	can	modify	disease	or	prevent	disease	progression,	
which	 are	 characteristics	 that	will	 be	 evaluated	 in	 the	 Preventing	
Asthma	in	high	Risk	Kids	(PARK)	study	in	the	United	States	(https://














ment	 rather	 than	 a	 universal	 “one‐size‐fits‐all”	 approach	 should	
be	 developed.	 The	 promising	 results	 of	 the	 recent	 Individualized	
Therapy	 for	 Persistent	Asthma	 in	Young	Children	 (INFANT)	 study	
support	this,	wherein	74%	of	children	showed	clinically	relevant	re‐
sponses	 to	 one	 treatment	 over	 others,	 and	 blood	 eosinophils	 and	
aeroallergen	sensitization	status	were	shown	to	be	useful	and	clini‐
cally	accessible	biomarkers	to	guide	response	to	treatment.66
4  | UNANSWERED QUESTIONS FOR 
OMALIZUMAB THER APY IN THE PEDIATRIC 
A STHMA POPUL ATION
Considerations	 for	 omalizumab	 therapy	 in	 pediatric	 patients	 are	
listed	 in	 Table	 3.	 Viruses,	 particularly	 rhinoviruses,	 are	 associated	
with	the	majority	of	asthma	exacerbations	in	children,	which	occur	
frequently	 during	 the	 autumnal	 season	 upon	 the	 recommence‐
ment	 of	 the	 school	 year.67	 Interestingly,	 reduced	 susceptibility	 to	
virus‐induced	 asthma	 exacerbations	 with	 omalizumab	 in	 children	
(6–17	years)	has	been	demonstrated.67,68	Mechanistically,	this	exac‐
erbation	reduction	 is	believed	to	be	 linked	to	enhanced	 interferon	
(IFN)‐α	responses.67	A	similar	impact	on	anti‐viral	responses	in	chil‐
dren	 has	 not	 yet	 been	 demonstrated	with	 another	 biologic	 agent,	
but	the	results	of	such	studies	would	be	important	additions	to	our	
scientific	 knowledge	 on	 exacerbation	 prevention	 and	 reduction	 in	
children.	The	true	potential	impact	of	early‐life	IgE	blockage	on	the	
future	development	of	 asthma	 remains	 to	be	 further	 investigated.	
The	results	of	the	PARK	and	EXPECT69	(discussed	later)	studies	may	
add	further	insights.
Pediatric	 asthma	 patients	 often	 suffer	 significant	 multi‐mor‐
bidity,	 including	 allergic	 rhinitis	 and	 food	 allergy.70,71	 Importantly,	
omalizumab	has	been	 shown	 to	be	effective	 in	allergic	 rhinitis	 (by	
significantly	 improving	 total	Rhinitis	Quality	 of	 Life	Questionnaire	
score).72	Furthermore,	 the	efficacy	of	omalizumab	 in	patients	with	
food	 allergy	 is	 encouraging;	 omalizumab	 decreased	 or	 eliminated	
food	allergy	 symptoms	upon	accidental	exposure	 to	 foods	against	
which	they	were	sensitized.73	However,	there	is	still	a	paucity	of	ev‐
idence	 for	 similar	 therapeutic	 action	 in	 affected	 patients	 <6	years	
of	age.	This	suggests	an	unmet	need	to	 investigate	the	efficacy	of	








the	 impact	of	anti‐IgE	 therapy	 in	extremely	polysensitized	asthma	
patients	are	still	lacking.
Although	 omalizumab	 is	 available	 for	 certain	 asthma	 patients	
aged	6–17	years,	 there	 is	still	 room	to	 improve	accessibility	to	this	
drug.	 The	 omalizumab	 dosing	 table	 is	 an	 important	 consideration,	
whereby	serum	IgE	 levels	and	body	weight	must	be	taken	 into	ac‐
count	when	calculating	drug	dose.	However,	patients	in	whom	pre‐




cians	 of	 children	 for	whom	 there	 are	 no	 alternative	 anti‐IgE	 ther‐




levels	throughout	childhood	have	been	recently	reported77 and may 
help	 in	 revising	 and	 expanding	 the	 criteria	 for	 eligibility	 for	 omal‐
izumab	 treatment.	 Finally,	 the	 fact	 that	 there	 are	 two	parameters	
(serum	IgE	and	body	weight)	involved	in	the	dosing	table	may	be	an	
added	complication	for	some	physicians.
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As	 omalizumab	 is	 a	 treatment	 that	 is	 administered	 every	 2	 or	
4	weeks,	 the	 opportunity	 to	 administer	 the	 medication	 at	 home	
would	be	of	great	benefit	for	both	patients	and	busy	parents/guard‐





Alternative	 biologic	 options	 with	 safe	 and	 flexible	 dosing	


















to	 omalizumab	 (via	 the	 feto‐maternal	 barrier)	 compared	 with	 the	
general	 asthma	population.69	Observational	 data	 for	 the	 newborn	
are	 also	 collected	 at	 birth,	 and	 at	 6	 and	 12	months	 post‐delivery	














asthma	control	 resulted	 in	 significant	cost	 savings	 through	 reduced	
healthcare	utilization.79	 In	order	 to	achieve	 this	globally,	 the	unmet	
needs	in	the	management	of	asthma	must	be	addressed.
As	asthma	is	one	of	the	most	common	conditions	affecting	chil‐
dren,1	 both	 primary	 care	 providers	 and	 specialists	 play	 important	
roles	 in	 diagnosis	 and	management.29	 Furthermore,	 dissemination	
and	implementation	of	evidence‐based	guidelines	to	ensure	efficient	
and	appropriate	escalation	of	therapy	are	critical.









































asthma	 patients	 are	 limited.	With	 more	 evidence	 of	 efficacy	 and	
safety	 in	 this	 vulnerable	 patient	 population,	 there	 is	 considerable	
potential	 for	 early	 intervention	 with	 omalizumab	 in	 these	 very	
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tients	 in	countries	where	asthma	 treatment	 is	 largely	delivered	by	
the	GP/PCP.14	An	increased	understanding	of	the	potential	benefits	
of	anti‐IgE	therapy	in	multi‐morbid	asthmatic	children	is	also	needed	
to	 ensure	 that	 patients	 are	 optimally	 treated,	 with	 specific	 label	
changes	implemented	where	appropriate.
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